Precision Medicines is dedicated to improving the lives of cancer patients through developing novel treatments that are targeted to genomically defined cancer sub types.
Precision co-develops targeted cancer therapies with companion biomarkers to direct treatment to those patients most likely to benefit from them.
Precision Medicines in-licenses oncology therapies from pharma, biotech, leading clinical and academic centres to develop alongside companion biomarkers.
Precision Medicines collaborate with biotech, pharma, academic and clinical centres globally to identify and develop novel cancer therapies and companion biomarkers for development.
Precision Medicines is led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and development, clinical oncology, and companion biomarkers.